Agenus’ (AGEN) Buy Rating Reiterated at HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $23.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 353.65% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird boosted their price objective on shares of Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research note on Wednesday, June 4th. Wall Street Zen cut shares of Agenus from a “buy” rating to a “hold” rating in a research note on Sunday, August 17th. Finally, Zacks Research raised shares of Agenus to a “hold” rating in a research note on Tuesday, August 12th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Agenus Price Performance

Shares of Agenus stock opened at $5.07 on Wednesday. The firm’s fifty day simple moving average is $5.20 and its 200-day simple moving average is $3.81. The stock has a market capitalization of $161.53 million, a price-to-earnings ratio of -0.71 and a beta of 1.44. Agenus has a 12 month low of $1.38 and a 12 month high of $7.34.

Agenus (NASDAQ:AGEN) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The firm had revenue of $25.70 million for the quarter, compared to analyst estimates of $49.71 million. Analysts anticipate that Agenus will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Several institutional investors have recently made changes to their positions in AGEN. Siren L.L.C. purchased a new stake in shares of Agenus during the 1st quarter worth $752,000. Marshall Wace LLP purchased a new stake in shares of Agenus in the 2nd quarter worth about $1,976,000. AQR Capital Management LLC boosted its position in shares of Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after buying an additional 427,604 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Agenus by 110.0% in the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after buying an additional 220,327 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Agenus in the 2nd quarter worth about $906,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.